High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma

Abstract

AbstractThere is no clear consensus on the most effective treatment for relapsed/refractory high‐risk neuroblastoma (NB). We retrospectively assessed seven NB patients with relapsed/refractory disease who received high‐dose carboplatin–irinotecan–temozolomide (HD‐CIT). Five of seven patients showed favorable therapeutic response (complete remission or partial remission). Regarding toxicity, the cytopenia period tended to prolong when more than three cycles were repeated, but nonhematological toxicities were controllable with general supportive care. Due to its antitumor efficacy and well‐tolerated nonhematologic toxicity, HD‐CIT is a promising salvage chemotherapy for relapsed/refractory NB. However, it is important to pay attention to the exacerbation of hematological toxicity when repeating the regimen.